Good Morning Investors!!! Wall Street came into the holiday week with a bit of pep, led by chip and tech names, while oil and gold also perked up. Overnight, the Japanese yen popped on fresh talk of support, which is a reminder that big currency swings can splash into U.S. stocks. Today is the main course: a Gross Domestic Product (GDP) update plus other key reads that can move bond interest rates and, in turn, stock prices. And in company news, Novo Nordisk just snagged U.S. Food and Drug Administration (FDA) approval for a weight-loss pill, which could widen the customer base for its blockbuster meds.
Key Market DriversChip stocks lead the way (again): U.S. stocks opened the holiday week with a bounce. The Standard and Poor’s 500 rose 0.64% and the Nasdaq Composite gained 0.52%, helped by chip leaders like Nvidia and Micron and fresh talk of more artificial intelligence (AI) demand.Chip stocks matter because tech is a huge part of the index. The Cboe Volatility Index (VIX) (market fear gauge) closed near 14, a one-year low, but trading is thin into Christmas, with an early close Wednesday and no market Thursday, so small news can jolt prices. 
Cboe Volatility Index (VIX) – 1 Year Chart
Oil and Gold wake up: Commodities had a caffeine shot on Monday. Brent crude (global oil benchmark) settled at $62.07 a barrel and West Texas Intermediate (WTI – the U.S. oil benchmark) ended at $58.01 after headlines tied to Venezuelan oil tankers. Gold and silver also hit fresh record highs overnight as traders paid up for safety. Oil matters because it can seep into gas prices and inflation, which then tugs on interest rates and stock values. Gold’s sprint can be a “uh-oh” sign, but it is also just a hedge for some portfolios. Yen bounce puts currencies back on the radar: Japan waved a bright yellow flag at currency traders. After officials warned they could step in to support the yen, the yen strengthened about 0.7% to roughly 155.9 per dollar as of early this morning. The Bank of Japan (BOJ – Japan’s central bank) raised rates, yet the yen stays jumpy. Big currency moves can ripple into stocks because many large firms sell goods abroad and report earnings in dollars. If the yen swings fast, it can also shift global money flows into and out of U.S. bonds. GDP day arrives (finally): Today’s main calendar event is the long-delayed Gross Domestic Product (GDP – the total size of the economy) report for the third quarter, due at 8:30 AM ET. The report was pushed back by a 43-day government shutdown, so markets have been flying a bit blind. Bond investors care because growth can shift yields (bond interest rates) fast. The 10-year Treasury yield (rate on a 10-year U.S. bond) was 4.17% on Monday, and a GDP surprise could change what markets expect from the Federal Reserve (Fed) (U.S. central bank). Update: Real GDP rose 4.3% (annual rate) in Q3, beating forecasts. Spending stayed strong. Inflation in the report also ran warm: Personal Consumption Expenditures (PCE) (Fed’s preferred inflation gauge) rose 2.8%. That mix can lift yields and pressure pricey stocks. |
Thoughts from InvestorsGrow:
Today is a big day when it comes to data. The big moment is 8:30 AM ET, when GDP hits along with corporate profits and durable goods. GDP is backward-looking, but markets still trade it because it shapes the story on growth. Annual rate just means “the pace if it ran for a year.”
If GDP comes in hotter than expected, bond yields could pop (yield = the interest rate you earn on a bond). That can be a headwind for high-growth stocks that live on future hopes. If GDP is soft, yields may cool, but too-soft can spark the “slowdown” talk. Then at 10:00 AM, consumer confidence is a quick gut-check on spending, and tomorrow’s jobless claims add a fresh pulse on jobs before markets head out early.
UPDATE: Quick read on the fresh GDP print: it was strong, and prices were not icy. Real GDP grew 4.3% in Q3, while Personal Consumption Expenditures (PCE) (Fed’s preferred inflation gauge) rose 2.8%, and core PCE (strips out food and energy) was 2.9%. That combo can cool hopes for fast rate cuts. Next checkpoint is 10:00 AM ET consumer confidence to see if shoppers still feel bold.
Digital Infrastructure Real Estate (Data Centers and Towers)
A real estate investment trust (REIT) (rent collecting real estate company) owns property and rents it out. In this niche, the “property” is data centers and cell towers. They matter because every stream, payment, and artificial intelligence (AI) tool needs power, cooling, and a fast link.
Data center dealmaking hit a record pace in 2025, about $61 billion through November, as firms race to add space for AI and cloud work. The big speed bump is electricity, since one site can pull as much power as a small town. Regulators are pushing for clearer rules on how these sites connect to the grid. The Pacer Data & Infrastructure Real Estate exchange-traded fund (ETF), SRVR, is down about 1% over the past five trading days as of Monday’s close.
Equinix (EQIX):
Equinix runs data centers that let customers park servers close to networks and clouds. Its edge is interconnection, meaning private links inside its sites that help move data fast. It recently reported record bookings, but big build costs and power needs are the trade-off.
Digital Realty Trust (DLR):
Digital Realty is a major data center landlord with big projects for large clients. It stands out for a large backlog of signed leases, which can add visibility into the next year. It recently posted record core cash earnings per share for a REIT, but a few large clients can drive a lot of growth.
GDS Holdings (GDS):
GDS builds and runs data centers in China, mainly near big cities. It reported about 10% revenue growth in its latest quarter while pointing to AI as a growth driver. Extra risk: China policy and funding swings can change the story fast.
InvestorsGrow Takeaway:
Think “rent checks from the cloud.” Watch power access and interest rates, since both can move these stocks in a hurry.
Novo Nordisk (NVO)
Novo Nordisk (NVO) is a Denmark-based drug maker that sells treatments for diabetes and weight loss. In plain terms, it makes meds that help people manage blood sugar and, for some, shed weight. Its hit products include Wegovy and Ozempic, which belong to a class called glucagon-like peptide-1 (GLP-1) (hunger hormone mimic) drugs. The company has become a key name in the weight-loss drug race.
Late Monday, the U.S. Food and Drug Administration (FDA) (America’s drug safety referee) approved a pill version of Wegovy for long-term weight management. It uses oral semaglutide, the same main ingredient as the Wegovy shot. Many people would rather take a pill than do a shot, so this could pull in new patients.
Why does Wall Street care? Convenience can be a big deal, and pills can be easier to store and travel with. In a 64-week study, people taking the pill lost about 16.6% of their body weight on average, which helps explain the buzz. Next up, investors will watch the early January 2026 launch, how steady supply is, and whether insurance plans make it affordable.
InvestorsGrow Takeaway:
Novo is trying to turn “same science, new form” into a restart button. If the roll out is smooth and demand holds, the stock can get a fresh growth story without needing a brand-new drug. Red flags include price cuts that squeeze profit, strong rivals with their own pills in the pipeline, and real-world use that may grow slower than the hype. Educational only, not investment advice.
